Beam Therapeutics Inc.
corporate_fare Company Profile
Beam Therapeutics Inc. (NASDAQ:BEAM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for BEAM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 9/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for BEAM spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- Beam's Risto-cel Clears Pivotal Sickle Cell Trial, BLA Filing Set for Year-End
- Beam Q3 Loss Widens to $134.4M; $1.0B Cash Funds Runway Into Mid-2029
- Beam Therapeutics Posts $1.28 Per-Share Loss for Third Quarter
- Beam's BEAM-301 Shows Proof of Concept in GSDIa, Restoring Glucose Production
- Beam Therapeutics Slides 9% as BEAM-302 Data Fails to Impress
Financial Snapshot
Short Interest & Short Volume
13.69 days to coverFINRA reported short interest of 26,082,937 shares in BEAM as of the October 30, 2026 settlement, a 0.6% decrease from the prior period — about 13.7 days to cover at its recent average daily volume. On November 20, 2026, 52.2% of BEAM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.